We audited the recovery characteristics of 51 patients who had undergone orthognathic maxillofacial surgery at a single center. Patients whose anesthesia had been maintained with intravenous propofol and remifentanil (n 5 21) had significantly higher pain scores during the first 4 hours after surgery than those whose anesthesia was maintained with volatile inhalational agents and longer-acting opioids (n 5 30) (P 5 .016). There was a nonsignificant trend towards shorter recovery times in the former group, while there were no differences in early postoperative opioid usage, hemodynamic parameters, or postoperative nausea and vomiting . Given that our data were collected retrospectively and without the ability to control for potential confounders, we interpret the results with caution. Notwithstanding these limitations, we believe this is the first report comparing the effects of different opioid-based anesthetic regimens on early recovery from orthognathic surgery, and we believe this report may be used as the starting point for a controlled study.
The genital-shrinking syndrome is a transient state of acute anxiety characterized by the triad of a deep-seated fear of penile shrinkage, its disappearance into the abdomen, and apprehension regarding inevitable impotence or even death. It is also known by the Malayo-Indonesian term ‘koro’. In the West, koro syndrome has been reported only in relation with various somatic, psychiatric and drug-induced disorders. The vast majority of non-psychiatric cases was related to neurological disorders or intoxication with cannabis or amphetamine. This is the first case of cannabis-induced koro-like syndrome ever reported in Greece.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.